AstraZeneca, which along with Oxford University developed one of the world’s most widely used Covid-19 vaccines, has invested heavily in cancer medicine in recent years.
AstraZeneca’s cancer drug is offering new hope for cancer patients around the world after the pharmaceutical giant said its breast cancer drug Enhertu significantly reduced the risk of dying or disease progression in women with advanced disease during a large clinical trial.
For women with meta
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
